BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• Business

  McKesson Reports Fiscal 2018 Second-Quarter Results

  McKesson Corporation today reported that revenues for the second quarter ended September 30, 2017, were $52.1 billion, up 4% compared to $50.0 billion a year ago.

  October 26, 2017

   · 

  49 min read
• Drug Development

  Menlo Therapeutics Initiates Enrollment in Phase II Clinical Trial with Serlopitant for Refractory Chronic Cough

  Menlo Therapeutics has initiated enrollment in a 170-subject Phase II trial evaluating serlopitant as a treatment for refractory chronic cough.

  October 26, 2017

   · 

  2 min read
• Chi-Med Announces Pricing of U.S. Public Offering of ADSs Raising US$262 Million on Nasdaq Global Select Market

  Hutchison China MediTech Limited announced today the pricing of the underwritten public offering previously announced by Chi-Med on October 24, 2017.

  October 26, 2017

   · 

  5 min read
• Policy

  FDA Accepts Genentech’s Supplemental Biologics License Application for Avastin as a Front-Line Treatment for Women With Advanced Ovarian Cancer

  Genentech announced today that the FDA has accepted the company’s supplemental Biologics License Application (sBLA) for Avastin (bevacizumab) in combination with chemotherapy (carboplatin and paclitaxel), followed by Avastin alone, for the front-line treatment of women with advanced ovarian cancer.

  October 26, 2017

   · 

  10 min read
• Business

  Medivir AB - Interim Report, January - September 2017

  Positive topline results from phase IIa osteoarthritis study showed disease-modifying benefit and an acceptable safety and tolerability in this patient population.

  October 26, 2017

   · 

  7 min read
• Angle PLC: Total Voting Rights

  ANGLE plc. announces that, following the announcement of 12 October 2017, 7,481,570 New Ordinary Shares have been issued pursuant to the Further Subscription.

  October 26, 2017

   · 

  3 min read
• Business

  Epidarex Capital Appoints Three Leading Industry Executives to its Advisory Board

  Epidarex Capital, an early-stage, transatlantic life science venture fund, announces the appointment of Dr. William R Sellers, William Burns and Dr. Frank M Armstrong to its advisory board.

  October 26, 2017

   · 

  6 min read
• ICON Reports Third Quarter 2017 Results

  ICON plc, a global provider of drug development solutions and services to the pharmaceutical, biotechnology and medical device industries, today reported its financial results for the third quarter ended September 30, 2017.

  October 26, 2017

   · 

  9 min read
• Business

  Ipsen Delivers Strong Sales Growth of 22.6% for the Third Quarter of 2017 and Confirms Full Year Guidance

  Ipsen, a global specialty-driven biopharmaceutical group, today announced sales for the third quarter of 2017.

  October 26, 2017

   · 

  29 min read
• Policy

  Mylan Wins U.K. Court Ruling Related to Copaxone 40 mg/mL Patent

  Mylan today announced that the United Kingdom’s High Court of Justice has issued a decision in favor of Mylan and its European partner Synthon, finding all claims of Teva’s patent EP (UK) 2 949 335 (EP 335) relating to Copaxone 40 mg/mL invalid based on obviousness.

  October 26, 2017

   · 

  5 min read